Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05891080

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer Clinical Trial

Official title:
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Clinical Trial Summary

For stage III non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients could not achieve complete pathological response (CPR). New immunotherapeutic strategy is needed to achieve higher CPR rate. JS004 is a new antibody targeting B and T lymphocyte attenuator (BTLA) which restrains the function of immune cells and leads to immune escape of tumor cells. The combination of PD-1 antibody and BTLA antibody has shown good therapeutic effect in solid tumors. This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 plus chemotherapy in stage III NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05891080
Study type Interventional
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact Peng Zhang, PhD
Phone 02165115006
Email zhangpeng1121@tongji.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2023
Completion date July 1, 2030
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05488626 - Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer N/A
Recruiting NCT02076282 - MRI Optimization Study in Stage III NSCLC N/A
Terminated NCT01577212 - Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy Phase 2
Withdrawn NCT01336543 - Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01102231 - Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT06082492 - The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients N/A
Active, not recruiting NCT03049618 - Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Phase 2
Recruiting NCT03077854 - Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial N/A
Recruiting NCT05157542 - Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC Phase 1
Recruiting NCT00938418 - Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05361174 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03048500 - Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 2
Active, not recruiting NCT01948141 - Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Phase 2
Completed NCT01282437 - Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC Phase 3
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Recruiting NCT05157503 - Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
Recruiting NCT05468242 - Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Active, not recruiting NCT06102057 - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC Phase 2
Recruiting NCT04984148 - Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC